Literature DB >> 1823080

Effect of octreotide on 24-hour growth hormone and prolactin secretory patterns in acromegalics.

B Schindel1, I Ashkenazi, R Keret, A Silbergeld, M Wasserman, M Lapidot, A G Harris, Z Laron.   

Abstract

Four adult patients with active acromegaly underwent studies of their 24-hour secretory pattern of hGH and Prl prior to and at the end of 3 months of treatment with the octreotide (somatostatin analog SMS 201-995) 100 micrograms s.c. every 8 h. Blood was withdrawn at 30-min intervals with the aid of a constant withdrawal pump. The best fit cosinor method was used to define the following rhythm parameters: mesor, amplitude, acrophase and periodicity. Prior to treatment, hGH secretion was increased in all patients. The mean 24-hour ranged from 9-47 ng/ml with amplitude 5.2-23 and observed maximal pulse 41-95 ng/ml. Computed rhythms were circadian in 3 patients and ultradian in 1; in 2 patients the acrophases were shifted to daytime. hPrl secretion was altered in 3 of the patients. Two had elevated mean 24-hour of 17.7 and 22.2 ng/ml, while computed rhythms showed semicircadian periodicity in 1 of them and circadian periodicity with a shift of acrophase to daytime in the other. The third patient who had normal hPrl levels, showed ultradian 8-hour periodicity. At the end of treatment there was a marked reduction in hGH secretion in 1 patient and a lesser reduction in the other 3. The rhythm was influenced by the masking effect of the drug, to yield an 8-hour period with acrophases related to injection clock time having equal amplitudes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1823080     DOI: 10.1159/000182164

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  1 in total

1.  The relationship between serum levels of prolactin and growth hormone in the early postnatal period.

Authors:  Jonathan Daliot; Tami Laron-Kenet; Mohammad Wattad; Anat Ben-Dor; Pearl Lilos; Zvi Laron
Journal:  Pediatr Res       Date:  2017-08-02       Impact factor: 3.756

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.